<DOC>
	<DOCNO>NCT01125943</DOCNO>
	<brief_summary>The introduction angiogenesis inhibitor remarkably improve treatment patient several type cancer . One report side effect angiogenesis inhibitor hypertension . In patient treated bevacizumab , monoclonal antibody vascular endothelial growth factor , hypertension overall incidence 32 % . The increase blood pressure occur early treatment . The etiology hypertension cause treatment angiogenesis inhibitor unclear . Understanding pathogenesis side effect essential optimal treatment class drug . The primary objective explore effect bevacizumab infusion endothelium-dependent vasodilation forearm resistance artery .</brief_summary>
	<brief_title>Bevacizumab Endothelium Dependent Vasodilation</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Nitroprusside</mesh_term>
	<mesh_term>Acetylcholine</mesh_term>
	<criteria>1 . Age 1850 year old 2 . Male 3 . Results serum glucose , lipids creatinine within laboratory 's reference range . 4 . Subject able willing sign Informed Consent Form prior screen evaluation . 1 . Documented history sensitivity/idiosyncrasy medicinal product excipients . 2 . History current abuse drug , alcohol solvent . 3 . History malignant disease . 4 . First degree relative history cancer age 50 5 . First degree relative history premature cardiovascular disease age 50 6 . Current use medication . 7 . Clinical evidence cardiac pulmonary disease 8 . Hypertension ( systole &gt; 140mmHG , diastole &gt; 90mmHg ) 9 . Diabetes mellitus 10 . Smoking 11 . Any clinically relevant abnormality ECG . 12 . A history thrombosis first degree family member history recurrent thrombosis 13 . Inability understand nature extent trial procedure require . 14 . Previous participation study bevacizumab</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>